These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22698523)

  • 1. No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells.
    Olesen M; Skov V; Mechta M; Mumm BH; Rasmussen LM
    Mol Cell Endocrinol; 2012 Oct; 362(1-2):149-56. PubMed ID: 22698523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
    Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.
    Di Bartolo BA; Cartland SP; Harith HH; Bobryshev YV; Schoppet M; Kavurma MM
    PLoS One; 2013; 8(9):e74211. PubMed ID: 24040204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.
    Callegari A; Coons ML; Ricks JL; Rosenfeld ME; Scatena M
    J Vasc Res; 2014; 51(2):118-31. PubMed ID: 24642764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification.
    Chasseraud M; Liabeuf S; Mozar A; Mentaverri R; Brazier M; Massy ZA; Kamel S
    Ther Apher Dial; 2011 Apr; 15(2):140-6. PubMed ID: 21426505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The function and meaning of receptor activator of NF-κB ligand in arterial calcification.
    Nie B; Zhou SQ; Fang X; Zhang SY; Guan SM
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):666-671. PubMed ID: 26489619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL, but Not R-Spondins, Is Involved in Vascular Smooth Muscle Cell Calcification through LGR4 Interaction.
    Fernández-Villabrille S; Martín-Vírgala J; Martín-Carro B; Baena-Huerta F; González-García N; Gil-Peña H; Rodríguez-García M; Fernández-Gómez JM; Fernández-Martín JL; Alonso-Montes C; Naves-Díaz M; Carrillo-López N; Panizo S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Wnt/β-Catenin Pathway in the Arterial Medial Calcification and Its Effect on the OPG/RANKL System.
    Nie B; Zhang SY; Guan SM; Zhou SQ; Fang X
    Curr Med Sci; 2019 Feb; 39(1):28-36. PubMed ID: 30868488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
    Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
    Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
    Chamoux E; Houde N; L'Eriger K; Roux S
    J Cell Physiol; 2008 Aug; 216(2):536-42. PubMed ID: 18338379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression.
    Xie H; Xie PL; Wu XP; Chen SM; Zhou HD; Yuan LQ; Sheng ZF; Tang SY; Luo XH; Liao EY
    Cardiovasc Res; 2011 Nov; 92(2):296-306. PubMed ID: 21750093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification.
    Osako MK; Nakagami H; Shimamura M; Koriyama H; Nakagami F; Shimizu H; Miyake T; Yoshizumi M; Rakugi H; Morishita R
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1287-96. PubMed ID: 23580147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
    McGonigle JS; Giachelli CM; Scatena M
    Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL attenuates RANKL-mediated osteoblastic signalling in vascular cell mono-culture and co-culture models.
    Harper E; Rochfort KD; Forde H; Davenport C; Smith D; Cummins PM
    PLoS One; 2017; 12(11):e0188192. PubMed ID: 29145460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.
    Corallini F; Celeghini C; Rimondi E; di Iasio MG; Gonelli A; Secchiero P; Zauli G
    J Cell Physiol; 2011 Sep; 226(9):2279-86. PubMed ID: 21660951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
    Sandra F; Hendarmin L; Nakamura S
    Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
    Carrillo-López N; Martínez-Arias L; Alonso-Montes C; Martín-Carro B; Martín-Vírgala J; Ruiz-Ortega M; Fernández-Martín JL; Dusso AS; Rodriguez-García M; Naves-Díaz M; Cannata-Andía JB; Panizo S
    Nephrol Dial Transplant; 2021 Mar; 36(4):618-631. PubMed ID: 33367746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain.
    Davenport C; Harper E; Rochfort KD; Forde H; Smith D; Cummins PM
    J Vasc Res; 2018; 55(2):111-123. PubMed ID: 29635231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 21 plays an inhibitory role in vascular calcification in vitro through OPG/RANKL system.
    Cao F; Liu X; Cao X; Wang S; Fu K; Zhao Y; Shen F; Liu J
    Biochem Biophys Res Commun; 2017 Sep; 491(3):578-586. PubMed ID: 28774557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin and kidney disease.
    Montañez-Barragán A; Gómez-Barrera I; Sanchez-Niño MD; Ucero AC; González-Espinoza L; Ortiz A
    J Nephrol; 2014 Dec; 27(6):607-17. PubMed ID: 24756971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.